Loading stock…

Medibank Private Limited (MPL) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Medibank Private Limited

MPLMarket cap $8.71BPrice $3.2

Country🇦🇺Australia

SectorFinancials

IndustryInsurance

Sells private health insurance to millions of Australians, covering hospital and extras care. It's the country's largest health insurer, holding roughly one in six Australians' policies, and was once fully government-owned before privatizing in 2014.

In Bastion Portfolios?

52W Return+7%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+9%7

Revenue Forecast

Rev CAGR (1y)+5%4

Rev CAGR (3y)+5%4

Rev CAGR (5y)+3%3

Earnings Forecast

EPS Growth Y+1+9%6

EPS Growth Y+2+7%6

EPS Growth Y+3+5%5

Quality

Margins

EBIT Margin10%4

Net Income Margin7%4

Free Cash Flow Margin5%4

Debt

Net Debt/EBITDA-0.310

Efficiency

ROE27%9

ROA14%9

Earnings Stability77

GEAR+STRONG71

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)185

P/E Ratio (Forward 3y)164

P/BV5.13

EV Multiples

EV/EBITDA Fwd145

EV/EBIT Fwd145

Yield

Free Cash Flow Yield0.0%6

Dividend Yieldna–

Momentum

Short term

1 month return-2%6

3 month return-7%4

YTD return-1%5

Mid term

Price vs 52wHigh88%7

1 year return-2%4

Long term

3 year return+47%5

5 year return+58%6

Risk Shield

Price Risk

Beta0.110

Volatility21%9

Free Cash Flow

Free Cash Flow Margin5%4

Free Cash Flow Yield0.0%6

Quality

ROCE34%9

Earnings Stability77

Net Debt/EBITDA-0.310

02Growth

Is it actually growing, and how fast?

MPLMedibank Private

Revenue FY26$6.4B

GROWTH RATING↗

WEAK34 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%7

Revenue, next 1Y+5%4

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+3%3

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+9%6

EPS growth, FY28E+7%6

EPS growth, FY29E+5%5

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 9%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 7%/yr vs revenue 5%/yr).

WATCH

A mid-pack grower, ahead of 34% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 9%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

WEAKNESSES

Over five years revenue is set to grow 3%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

MPLMedibank Private

Total return Current110%

Price return Current47.8%

MOMENTUM RATING↗

AVERAGE46 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%6

3-month return-7%4

YTD return-1%5

MID & LONG-TERM▾SCORE

% of 52-week high88%7

1-year return-2%4

3-year return+47%5

5-year return+58%6

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+47% over three years and +58% over five), roughly average for the market.

It's down 2% over the past year, now 12% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-2%), over three months (-7%) and so far this year (-1%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Medibank Private Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MPLMedibank Private

Revenue FY26$6.4B

GROWTH RATING↗

WEAK34 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%7

Revenue, next 1Y+5%4

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+3%3

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+9%6

EPS growth, FY28E+7%6

EPS growth, FY29E+5%5

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 9%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 7%/yr vs revenue 5%/yr).

WATCH

A mid-pack grower, ahead of 34% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 9%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

WEAKNESSES

Over five years revenue is set to grow 3%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

MPLMedibank Private

Total return Current110%

Price return Current47.8%

MOMENTUM RATING↗

AVERAGE46 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%6

3-month return-7%4

YTD return-1%5

MID & LONG-TERM▾SCORE

% of 52-week high88%7

1-year return-2%4

3-year return+47%5

5-year return+58%6

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+47% over three years and +58% over five), roughly average for the market.

It's down 2% over the past year, now 12% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-2%), over three months (-7%) and so far this year (-1%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Medibank Private Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community